Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication

Abstract Epidermal growth factor receptor (EGFR) kinase domain duplication (KDD) has been identified as an oncogenic driver in 0.05% to 0.14% of non–small cell lung cancer (NSCLC) patients. However, little is known of the efficacy of EGFR tyrosine kinase inhibitors (TKIs) for such patients. Here, we...

Full description

Bibliographic Details
Main Authors: Esuteru Hirokawa, Satomi Watanabe, Kazuko Sakai, Masayuki Takeda, Chihiro Sato, Takayuki Takahama, Kazuto Nishio, Kazuhiko Nakagawa
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Thoracic Cancer
Subjects:
carcinomatous meningitis
epidermal growth factor receptor (EGFR)
kinase domain duplication
tyrosine kinase inhibitor (TKI)
Online Access:https://doi.org/10.1111/1759-7714.14081
id doaj-b44312130d5d4ff78950aefbf9a4ec26
record_format Article
spelling doaj-b44312130d5d4ff78950aefbf9a4ec262021-08-16T04:32:27ZengWileyThoracic Cancer1759-77061759-77142021-08-0112162283228710.1111/1759-7714.14081Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplicationEsuteru Hirokawa0Satomi Watanabe1Kazuko Sakai2Masayuki Takeda3Chihiro Sato4Takayuki Takahama5Kazuto Nishio6Kazuhiko Nakagawa7Department of Medical Oncology Kindai University Faculty of Medicine Osaka JapanDepartment of Medical Oncology Kindai University Faculty of Medicine Osaka JapanDepartment of Genome Biology Kindai University Faculty of Medicine Osaka JapanDepartment of Medical Oncology Kindai University Faculty of Medicine Osaka JapanDepartment of Medical Oncology Kindai University Faculty of Medicine Osaka JapanDepartment of Medical Oncology Kindai University Faculty of Medicine Osaka JapanDepartment of Genome Biology Kindai University Faculty of Medicine Osaka JapanDepartment of Medical Oncology Kindai University Faculty of Medicine Osaka JapanAbstract Epidermal growth factor receptor (EGFR) kinase domain duplication (KDD) has been identified as an oncogenic driver in 0.05% to 0.14% of non–small cell lung cancer (NSCLC) patients. However, little is known of the efficacy of EGFR tyrosine kinase inhibitors (TKIs) for such patients. Here, we report the case of a 45‐year‐old Japanese woman with NSCLC positive for EGFR‐KDD (duplication of exons 18–25) who developed carcinomatous meningitis and showed a marked response to the EGFR‐TKIs erlotinib and osimertinib. As far as we are aware, this is the first report of EGFR‐TKI efficacy for carcinomatous meningitis in a NSCLC patient harboring EGFR‐KDD.https://doi.org/10.1111/1759-7714.14081carcinomatous meningitisepidermal growth factor receptor (EGFR)kinase domain duplicationtyrosine kinase inhibitor (TKI)
collection DOAJ
language English
format Article
sources DOAJ
author Esuteru Hirokawa
Satomi Watanabe
Kazuko Sakai
Masayuki Takeda
Chihiro Sato
Takayuki Takahama
Kazuto Nishio
Kazuhiko Nakagawa
spellingShingle Esuteru Hirokawa
Satomi Watanabe
Kazuko Sakai
Masayuki Takeda
Chihiro Sato
Takayuki Takahama
Kazuto Nishio
Kazuhiko Nakagawa
Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
Thoracic Cancer
carcinomatous meningitis
epidermal growth factor receptor (EGFR)
kinase domain duplication
tyrosine kinase inhibitor (TKI)
author_facet Esuteru Hirokawa
Satomi Watanabe
Kazuko Sakai
Masayuki Takeda
Chihiro Sato
Takayuki Takahama
Kazuto Nishio
Kazuhiko Nakagawa
author_sort Esuteru Hirokawa
title Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
title_short Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
title_full Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
title_fullStr Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
title_full_unstemmed Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
title_sort durable response to egfr tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an egfr kinase domain duplication
publisher Wiley
series Thoracic Cancer
issn 1759-7706
1759-7714
publishDate 2021-08-01
description Abstract Epidermal growth factor receptor (EGFR) kinase domain duplication (KDD) has been identified as an oncogenic driver in 0.05% to 0.14% of non–small cell lung cancer (NSCLC) patients. However, little is known of the efficacy of EGFR tyrosine kinase inhibitors (TKIs) for such patients. Here, we report the case of a 45‐year‐old Japanese woman with NSCLC positive for EGFR‐KDD (duplication of exons 18–25) who developed carcinomatous meningitis and showed a marked response to the EGFR‐TKIs erlotinib and osimertinib. As far as we are aware, this is the first report of EGFR‐TKI efficacy for carcinomatous meningitis in a NSCLC patient harboring EGFR‐KDD.
topic carcinomatous meningitis
epidermal growth factor receptor (EGFR)
kinase domain duplication
tyrosine kinase inhibitor (TKI)
url https://doi.org/10.1111/1759-7714.14081
work_keys_str_mv AT esuteruhirokawa durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT satomiwatanabe durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT kazukosakai durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT masayukitakeda durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT chihirosato durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT takayukitakahama durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT kazutonishio durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT kazuhikonakagawa durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
_version_ 1721206027203903488

Similar Items